Platelets-derived vesicles: innovative subcellular platforms for management of multiple sclerosis

Abstract

Abstract Multiple sclerosis (MS) is a progressive inflammatory autoimmune disease that involves young individuals. The drug delivery systems now are available for this disease have chronic and non-targeted effects in the patients, and because of the presence of BBB, their concentration in the CNS is low. Because of this flaw, it is critical to use innovative active targeted drug delivery methods. Platelets are blood cells that circulate freely and play an important role in blood hemostasis. In this review, we emphasize the various roles of activated platelets in the inflammatory condition to recruit other cells to the injured area and limit the inflammation. Besides, the activated platelets in the different stages of the MS disease play a significant role for limiting the progression of inflammation in the peripheral area and CNS. This evidence indicates that platelet-based drug delivery system can be an efficient candidate for drug targeting to the CNS and limiting the inflammation in the peripheral and central areas for MS therapy.